Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium

Author:

Robbins Hilary A.1ORCID,Ferreiro-Iglesias Aida1,Waterboer Tim2,Brenner Nicole2ORCID,Nygard Mari3ORCID,Bender Noemi2ORCID,Schroeder Lea2,Hildesheim Allan4ORCID,Pawlita Michael2,D'Souza Gypsyamber5ORCID,Visvanathan Kala5,Langseth Hilde67ORCID,Schlecht Nicolas F.89ORCID,Tinker Lesley F.10,Agalliu Ilir9ORCID,Wassertheil-Smoller Sylvia9ORCID,Ness-Jensen Eivind111213,Hveem Kristian14ORCID,Grioni Sara15,Kaaks Rudolf16ORCID,Sánchez Maria-Jose17181920,Weiderpass Elisabete21ORCID,Giles Graham G.222324ORCID,Milne Roger L.222324ORCID,Cai Qiuyin25,Blot William J.25,Zheng Wei25ORCID,Weinstein Stephanie J.4ORCID,Albanes Demetrius4,Huang Wen-Yi4ORCID,Freedman Neal D.4,Kreimer Aimée R.4,Johansson Mattias1ORCID,Brennan Paul1ORCID

Affiliation:

1. Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France

2. Division of Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany

3. Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway

4. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD

5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

6. Department of Research, Cancer Registry of Norway, Oslo, Norway

7. Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom

8. Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY

9. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY

10. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA

11. HUNT Research Center and K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Levanger/Trondheim, Norway

12. Department of Medicine, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway

13. Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

14. HUNT Research Center and K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway

15. Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy

16. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany

17. Escuela Andaluza de Salud Pública (EASP), Granada, Spain

18. Instituto de Investigación Biosanitaria (ibs.GRANADA), Granada, Spain

19. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain

20. Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain

21. International Agency for Research on Cancer, Lyon, France

22. Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia

23. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Australia

24. Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

25. Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN

Abstract

PURPOSE Seropositivity for the HPV16-E6 oncoprotein is a promising marker for early detection of oropharyngeal cancer (OPC), but the absolute risk of OPC after a positive or negative test is unknown. METHODS We constructed an OPC risk prediction model that integrates (1) relative odds of OPC for HPV16-E6 serostatus and cigarette smoking from the human papillomavirus (HPV) Cancer Cohort Consortium (HPVC3), (2) US population risk factor data from the National Health Interview Survey, and (3) US sex-specific population rates of OPC and mortality. RESULTS The nine HPVC3 cohorts included 365 participants with OPC with up to 10 years between blood draw and diagnosis and 5,794 controls. The estimated 10-year OPC risk for HPV16-E6 seropositive males at age 50 years was 17.4% (95% CI, 12.4 to 28.6) and at age 60 years was 27.1% (95% CI, 19.2 to 45.4). Corresponding 5-year risk estimates were 7.3% and 14.4%, respectively. For HPV16-E6 seropositive females, 10-year risk estimates were 3.6% (95% CI, 2.5 to 5.9) at age 50 years and 5.5% (95% CI, 3.8 to 9.2) at age 60 years and 5-year risk estimates were 1.5% and 2.7%, respectively. Over 30 years, after a seropositive result at age 50 years, an estimated 49.9% of males and 13.3% of females would develop OPC. By contrast, 10-year risks among HPV16-E6 seronegative people were very low, ranging from 0.01% to 0.25% depending on age, sex, and smoking status. CONCLUSION We estimate that a substantial proportion of HPV16-E6 seropositive individuals will develop OPC, with 10-year risks of 17%-27% for males and 4%-6% for females age 50-60 years in the United States. This high level of risk may warrant periodic, minimally invasive surveillance after a positive HPV16-E6 serology test, particularly for males in high-incidence regions. However, an appropriate clinical protocol for surveillance remains to be established.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3